← All organizations
Bracco
Also known as: Blue Earth Therapeutics | Blue Earth Therapeutics Ltd | BRACCO | Bracco Corporate | Bracco Diagnostics | Bracco Diagnostics Inc. | Bracco Diagnostics, Inc | BRACCO DIAGNOSTICS INC | Bracco Dianostics, Inc. | Bracco Imaging S.p.A. | Bracco (Sponsor)
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2004First marketed drug
Apr 27, 1954First NDA
Apr 27, 1954Last known activity
Aug 1, 2025
Timeline
1920s
- Jan 1, 1927
Bracco— Founded
1970s
- Dec 21, 1970
cyanocobalamin— Marketing Organization
1980s
- Aug 14, 1981
iodoxamate meglumine— NDA Organization
- Aug 14, 1981
iodoxamate meglumine— NDA Secondary Org
2010s
- Jun 27, 2019
Blue Earth Diagnostics— Acquired
Drugs by trial phase (25 distinct, 82 trials)
Phase 4 (10 own, 2 via acquisition)
Phase 3 (3 own, 1 via acquisition)
Phase 2 (3 own, 3 via acquisition)
Phase 1 (2 own, 1 via acquisition)
Indications
Approved for
- Anemia, Hemolytic
- Biliary Tract Diseases
- Breast Neoplasms
- Contrast Media
- Gallbladder Diseases
- Gastrointestinal Diseases
- Heart Diseases
- Hyperthyroidism
- Liver Diseases
- Malnutrition
- Melanoma
- Metabolic Diseases
- Osteoporosis
- Pancreatic Diseases
- Polycythemia
- Premenstrual Syndrome
- Spherocytosis, Hereditary
- Thyroid Neoplasms
- Vesico-Ureteral Reflux
Studied for
- Adenocarcinoma
- Arterial Occlusive Diseases
- Brain Diseases
- Brain Neoplasms
- Breast Neoplasms
- Central Nervous System Diseases
- Coronary Artery Disease
- Coronary Disease
- Coronary Stenosis
- Embolism
- Heart Diseases
- Hypertension
- Hypertension, Pulmonary
- Hypothyroidism
- Kidney Diseases
- Liver Neoplasms
- Myocardial Ischemia
- Neoplasms
- Nervous System Diseases
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Prostatic Neoplasms
- Pulmonary Embolism
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Vascular Diseases
Marketed drugs (38)
- barium sulphate
- Iomeprol
- cyanocobalamin
- iopamidol
- gadoteridol
- intrinsic factor
- sincalide
- sulfur hexafluoride lipid-type a microspheres
- radiolabeled albumin technetium Tc-99m albumin colloid kit
- technetium tc-99m sulfur colloid kit
- cellulose
- diatrazoate meglumine
- iodamide
- ipodate
- rose bengal sodium i-131
- selenomethionine se-75
- technetium tc-99m ferpentetate kit
- technetium tc-99m pyrophosphate
- ultra-technekow fm
- iodipamide meglumine
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT06516510Lead sponsorEarly Phase 1Oct 31, 2024
- NCT06516510OfficialEarly Phase 1Oct 31, 2024
- NCT06406517CollaboratorPhase 3May 31, 2024
- NCT06400004Lead sponsorPhase 3Apr 30, 2024
- NCT06066437CollaboratorPhase 1/Phase 2Dec 31, 2023
- NCT06010173CollaboratorPhase 3Jul 21, 2023
- NCT05413850Lead sponsorPhase 1/Phase 2Jul 20, 2022
- NCT05413850Study directorPhase 1/Phase 2Jul 20, 2022
- NCT05286593CollaboratorPhase 4Dec 28, 2021
- NCT04973007CollaboratorPhase 4Jun 22, 2021
- NCT04373564CollaboratorPhase 4Jul 1, 2020
- NCT04340180CollaboratorPhase 1Jun 30, 2020
- NCT04248153Study directorPhase 2Oct 14, 2019
- NCT04248153Lead sponsorPhase 2Oct 14, 2019
- NCT03779906Lead sponsorPhase 4Feb 1, 2019
Details
- Founded
- Milan, IT Jan 1, 1927
- First NDA
- Apr 27, 1954
- Last known activity
- Aug 1, 2025
Designations held
- Priority review